Torrent Pharma Q4 Review - Steady Outperformance In Branded Generics Segment: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Torrent Pharmaceuticals Ltd.'s Q4 FY21 results were marginally below our estimates at an operational level, led by a sharp YoY decline in U.S. and contract research and manufacturing service sales.
It continues to build its product portfolio and enhance marketing efforts to outperform in Brazil, Germany, and the branded generics segment in domestic formulation.
It is also working on alternate site filings to reduce the regulatory risk in the U.S. generics business.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.